Related Experiment Video
Updated: Jun 21, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Wild-type p53 protects normal cells against apoptosis induced by thiostrepton
Abstract:
Cancer cells are generally more sensitive to anticancer drugs than normal cells. This provides the rationale for using anticancer drugs specifically against tumor cells, but the explanation for the specificity is often elusive. In this study, we compared the sensitivity of normal BJ human fibroblasts, BJ fibroblasts with p53 knockdown and corresponding BJ immortal/oncogenic cell lines with inactivated p53 to anticancer drug-induced apoptosis. We found that only normal cells that have wild-type p53 were resistant to the thiazole antibiotic, thiostrepton, suggesting that p53 plays an antiapoptotic role in normal cells. In this case p53 status, but not the transformation of cells per se determines their sensitivity to thiostrepton and possibly to other anticancer drugs. Since p53 is mutated in 50% of human cancers, thiostrepton may selectively kill cancer, but not normal cells. These data imply that wild-type p53 can protect normal cells from anticancer drug-induced cell death and its mutations may sensitize cancer cells to anti-neoplastic agents.
Insights
Normal cells with wild-type p53 resist the drug thiostrepton, indicating p53
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Anticancer drug efficacy relies on tumor cell specificity, yet mechanisms remain unclear.
- This study investigates differential drug sensitivity in normal versus cancer cells.
- Focus is on the role of p53 in mediating cellular response to anticancer agents.
Discussion:
- Wild-type p53 confers resistance to thiostrepton in normal fibroblasts.
- p53 status, not cellular transformation, dictates thiostrepen sensitivity.
- This suggests p53's anti-apoptotic function in normal cells.
Key Insights:
- Normal cells with wild-type p53 are resistant to thiostrepton.
- p53 mutations in cancer may sensitize cells to thiostrepen.
- Wild-type p53 protects normal cells from drug-induced apoptosis.
Outlook:
- Thiostrepton shows potential for selective cancer cell killing.
- Further research into p53's role could identify new therapeutic targets.
- Investigating other anticancer drugs for p53-dependent sensitivity is warranted.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Negative Regulator Molecules
Inhibition of Cdk Activity

